Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes $2.05 Million Position in Abbott Laboratories $ABT

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Abbott Laboratories (NYSE:ABT) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,394 shares of the healthcare product maker’s stock, valued at approximately $2,054,000.

A number of other large investors also recently made changes to their positions in ABT. Harbor Capital Advisors Inc. acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $27,000. Cloud Capital Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $31,000. Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $33,000. Finally, Copia Wealth Management acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,055 shares of company stock valued at $353,097. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Down 0.5%

Shares of NYSE ABT opened at $88.38 on Thursday. The stock has a market cap of $153.93 billion, a price-to-earnings ratio of 24.76, a PEG ratio of 1.48 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The business has a 50 day simple moving average of $97.65 and a 200 day simple moving average of $112.47. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.9%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ABT. Oppenheimer lowered their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research note on Wednesday, April 22nd. Raymond James Financial lowered their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Weiss Ratings cut Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, April 24th. Finally, BTIG Research reissued a “buy” rating and issued a $131.00 price target on shares of Abbott Laboratories in a research note on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $119.43.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.